PEDIATRICS Vol. 24 No. 4 October 1959, pp. 544-561
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by C. Tan, C. T.
Right arrow Articles by Burchenal, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by C. Tan, C. T.
Right arrow Articles by Burchenal, J. H.

THE EFFECT OF ACTINOMYCIN D ON CANCER IN CHILDHOOD

Charlotte T. C. Tan M.D.1, Harold W. Dargeon M.D.1, and Joseph H. Burchenal M.D.1

1 Division of Clinical Chemotherapy, Sloan-Kettering Institute, Departments of Pediatrics and Medicine, Memorial Hospital, Memorial Center for Cancer and Allied Diseases, New York, and Cornell University Medical College

Actinomycin D has a slight but definite effect in producing regression of tumors in patients with cancer. Wilms' tumor and lymphomas have shown better response than other tumors. Although the effect of the combination of actinomycin D and x-ray therapy is difficult to evaluate, these agents appear to be additive in producing temporary regression of the tumor in some patients.

The usual single course of actinomycin D intravenously is 75 µ.g/kg of body weight divided into four or five daily doses. The oral dose of actinomycin D is 3 to 10 mg daily. About 5% of actinomycin D given orally is absorbed as evidenced by production of systemic toxicity. However, severe local gastrointestinal effect usually prevents adequate oral administration of the drug.

The toxic effects of actinomycin D are local on the gastrointestinal tract with ulceration of the mouth, nausea, vomiting, anorexia, occasional abdominal pain and diarrhea; exacerbation of skin reaction in previously irradiated areas; alopecia; decrease in leukocyte and platelet counts. The toxicity after intravenous administration of actinomycin D usually develops within the first 2 weeks and disappears within the next 2 weeks.

The duration of improvement after a single course of actinomycin D intravenously was usually from 1 to 10 weeks. Two children, one with Wilms' tumor and one with embryonal carcinoma, had no recurrence for 24 and 7 months, respectively. Both received maintenance doses of actinomycin D orally.

Submitted on March 13, 1959
Accepted on April 27, 1959